The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 in Paris, France (21–24 May).
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today excellent long-term results of its CE Mark-approved DESyne® BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating compared to the control Endeavor Zotarolimus Eluting Coronary Stent System with durable coating in the EXCELLA BD randomized clinical trial at the 2-year endpoint.
En un estudio sobre miles de pacientes que habían tenido un infarto, los que recordaron haber tenido un brote de ira el año anterior eran dos veces más propensos a haber tenido el infarto dentro de las dos horas posteriores que en otros momentos de ese año. "Existe un aumento transitorio del riesgo de padecer un infarto después de un brote de ira", dijo la autora principal, Elizabeth Mostofsky, investigadora postdoctoral de la Unidad de Investigación Epidemiológica Cardiovascular de la Facultad de Medicina de Harvard, Boston.
The delayed healing of the coronary artery following implantation of of drug-eluting stents, which increases patients’ risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris, France (21–24 May).
OrbusNeich today announced that the companys Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an investigator-initiated randomized study, were published in the June issue of Minerva Cardioangiologica.
BioMatrix NeoFlex, according to the company, has received the CE mark and features a new advanced stent delivery system to improve pushability, trackability and crossability. It also has a lower lesion entry profile than its predecessor. BioMatrix NeoFlex retains the same combination of abluminal biodegradable polymer coating, proprietary limus drug Biolimus A9 (BA9).
The Radboud University Nijmegen Medical Centre (Nijmegen, the Netherlands) and Main-Taunus Cardiac Center (Bad Soden, Germany) announced the results of a clinical study that demonstrated the safety for patients and clinicians can be significantly enhanced during cardiac interventions. Using Philips’ recently introduced AlluraClarity system with ClarityIQ technology, the doctors of the medical centre were (according to the company), for the first time, able to achieve a 50% reduction in X-ray dose while maintaining the excellent image quality needed during image-guided cardiac interventions. The results are expected to be presented during EuroPCR, 21– 24 May in Paris, France.
Un meta-análisis demuestra que la aspiración del trombo antes de la angioplastia reduce los eventos adversos cardíacos importantes (MACE, por su sigla en inglés) en los pacientes con un infarto agudo de miocardio. No obstante, la trombectomía por aspiración manual no modifica el tamaño final del infarto.
Un estudio revela que las estadísticas públicas de la evolución de los pacientes después de una intervención cardíaca común suelen ser imprecisas. La proporción de pacientes que mueren dentro de los 30 días posteriores a un procedimiento médico se utiliza para determinar la efectividad del tratamiento o de la calidad hospitalaria o de los profesionales.
Un estudio prolongado demuestra que el uso de un solo stent es la mejor estrategia para tratar las lesiones en las bifurcaciones de las arterias coronarias. En el Estudio Nórdico sobre Bifurcaciones, a la mitad de los pacientes se les implantó un stent liberador de fármacos en el vaso principal (VP) con un stent opcional en la rama lateral (RL) y al resto se les colocaron stents en el VP y la RL.
Un metaanálisis prueba que las infusiones de células madre todavía deben demostrar que pueden mejorar el tratamiento de la enfermedad cardíaca. "La terapia con células madre está provocando un gran entusiasmo como enfoque terapéutico potencial, pero aún es muy pronto para utilizarla", dijo por e-mail el autor principal, doctor Jagmeet Singh, director del Programa de Terapia de Resincronización Cardíaca del Hospital General de Massachusetts, Boston.
The Food and Drug Administration (FDA) has given Elixir Medical the go ahead to start patient enrolment for its investigational device exemption (IDE) EXCELLA III clinical trial, which will be used to support pre-market approval of the company’s Desyne Nx novolimus-eluting stent system.
A study published ahead of print in the Journal of the American College of Cardiology suggests that the use of transcatheter aortic valve implantation (TAVI) devices varies greatly across Europe and that, overall, the therapy is underused. Furthermore, the study indicates that this underuse is closely associated with national economic indices and reimbursement strategies.
Sorin has announced that it has received conditional approval from the Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) study of its Perceval S sutureless aortic valve. The primary objective of the prospective, non-randomised trial is to demonstrate the safety and effectiveness of the valve in support of receiving FDA pre-market approval clearance.
According to a study published in Circulation Journal, a simple risk score could be used to predict which patients are at high risk of bleeding after a percutaneous coronary intervention (PCI) procedure. Additionally, a patient’s risk of bleeding (low, intermediate, or high) could be used to direct choice of treatment (eg. bare metal stent or drug-eluting stent).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos